Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro

Zhu,Jinhui; Ji,Yun; Yu,Yuanquan; Jin,Yun; Zhang,Xiaoxiao; Zhou,Jiale; Chen,Yan

doi:10.3892/ol.2018.8363

Knockdown of serine/threonine protein phosphatase 5 enhances gemcitabine sensitivity by promoting apoptosis in pancreatic cancer cells in vitro

Authors:
- Jinhui Zhu
- Yun Ji
- Yuanquan Yu
- Yun Jin
- Xiaoxiao Zhang
- Jiale Zhou
- Yan Chen
View Affiliations

Affiliations: Department of General Surgery and Laparoscopic Center, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China, Department of General Surgery, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, P.R. China
Published online on: March 28, 2018 https://doi.org/10.3892/ol.2018.8363
Pages: 8761-8769

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The targeting protein of serine/threonine protein phosphatase 5 (PPP5C) has been reported to be present in various malignancies. However, its functional role in pancreatic cancer (PC) remains unknown. In the present study, the function of PPP5C in PC cells treated with the first‑line drug gemcitabine (GEM) was investigated. Short hairpin (sh)RNA targeting PPP5C was constructed to knockdown PPP5C in PANC‑1 cells. Cell cycle and apoptosis analyses were performed in order to investigate the mechanisms underlying the effects induced by PPP5C silencing combined with GEM treatment. Western blot analysis was applied to detect the expression of certain key regulators of cell apoptosis in PANC‑1 cells treated with GEM. shRNA against PPP5C effectively suppressed the proliferation of PANC‑1 cells treated with GEM. Additionally, cell cycle analysis indicated that PPP5C knockdown resulted in a higher number of PANC‑1 cells treated with GEM in G0/G1 phase arrest. Knockdown of PPP5C increased the expression of associated apoptotic markers, including cleaved caspase 3, poly (ADP‑ribose) polymerase and phosphorylated (p)‑p53. In addition, the combination of treatment with GEM and PPP5C silencing significantly increased the apoptosis of PANC‑1 cells by affecting the expression levels of p‑c‑Jun N‑terminal kinases and p‑p38. The present study suggests that PPP5C may be a potential target for the treatment of PC and that it may enhance the gemcitabine sensitivity of PC cells.

View Figures

View References

1	Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
2	Hurton S, MacDonald F, Porter G, Walsh M and Molinari M: The current state of pancreatic cancer in Canada: Incidence, mortality, and surgical therapy. Pancreas. 43:879–885. 2014. View Article : Google Scholar : PubMed/NCBI
3	Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J and Nagino M: Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer. Cancer Med. 4:1091–1100. 2015. View Article : Google Scholar : PubMed/NCBI
4	Zuo J, Zhang C, Ren C, Pang D, Li Y, Xie X, Tang Z and Jiang X: Secretory leukocyte protease inhibitor is a proliferation and survival factor for pancreatic cancer cells. Clin Transl Oncol. 17:314–321. 2015. View Article : Google Scholar : PubMed/NCBI
5	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
6	Funel N, Del Chiaro M, Cahen DL and Laukkarinen J: Pancreatic cancer. Gastroenterol Res Pract. 2015:8090362015. View Article : Google Scholar : PubMed/NCBI
7	Thota R, Pauff JM and Berlin JD: Treatment of metastatic pancreatic adenocarcinoma: A review. Oncology (Williston Park). 28:70–74. 2014.PubMed/NCBI
8	Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
9	Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
10	Tempero MA, Behrman S, Ben-Josef E, Benson AB III, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, et al: Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 3:598–626. 2005. View Article : Google Scholar : PubMed/NCBI
11	Oettle H and Riess H: Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer. Cancer. 95:912–922. 2002. View Article : Google Scholar : PubMed/NCBI
12	Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 27:3778–3785. 2009. View Article : Google Scholar : PubMed/NCBI
13	Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study. J Clin Oncol. 28:1645–1651. 2010. View Article : Google Scholar : PubMed/NCBI
14	Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008. View Article : Google Scholar : PubMed/NCBI
15	Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 28:3605–3610. 2010. View Article : Google Scholar : PubMed/NCBI
16	Minami K, Shinsato Y, Yamamoto M, Takahashi H, Zhang S, Nishizawa Y, Tabata S, Ikeda R, Kawahara K, Tsujikawa K, et al: Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. J Pharmacol Sci. 127:319–325. 2015. View Article : Google Scholar : PubMed/NCBI
17	Cohen PT: Novel protein serine/threonine phosphatases: Variety is the spice of life. Trends Biochem Sci. 22:245–251. 1997. View Article : Google Scholar : PubMed/NCBI
18	Cohen PT, Brewis ND, Hughes V and Mann DJ: Protein serine/threonine phosphatases; an expanding family. FEBS Lett. 268:355–359. 1990. View Article : Google Scholar : PubMed/NCBI
19	Morita K, Saitoh M, Tobiume K, Matsuura H, Enomoto S, Nishitoh H and Ichijo H: Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress. EMBO J. 20:6028–6036. 2001. View Article : Google Scholar : PubMed/NCBI
20	Douglas P, Moorhead GB, Ye R and Lees-Miller SP: Protein phosphatases regulate DNA-dependent protein kinase activity. J Biol Chem. 276:18992–18998. 2001. View Article : Google Scholar : PubMed/NCBI
21	von Kriegsheim A, Pitt A, Grindlay GJ, Kolch W and Dhillon AS: Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5. Nat Cell Biol. 8:1011–1016. 2006. View Article : Google Scholar : PubMed/NCBI
22	Yong WH, Ueki K, Chou D, Reeves SA, von Deimling A, Gusella JF, Mohrenweiser HW, Buckler AJ and Louis DN: Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. Genomics. 29:533–536. 1995. View Article : Google Scholar : PubMed/NCBI
23	Yang J, Roe SM, Cliff MJ, Williams MA, Ladbury JE, Cohen PT and Barford D: Molecular basis for TPR domain-mediated regulation of protein phosphatase 5. EMBO J. 24:1–10. 2005. View Article : Google Scholar : PubMed/NCBI
24	Hinds TD Jr and Sánchez ER: Protein phosphatase 5. Int J Biochem Cell Biol. 40:2358–2362. 2008. View Article : Google Scholar : PubMed/NCBI
25	Chinkers M: Protein phosphatase 5 in signal transduction. Trends Endocrinol Metab. 12:28–32. 2001. View Article : Google Scholar : PubMed/NCBI
26	Golden T, Swingle M and Honkanen RE: The role of serine/threonine protein phosphatase type 5 (PP5) in the regulation of stress-induced signaling networks and cancer. Cancer Metastasis Rev. 27:169–178. 2008. View Article : Google Scholar : PubMed/NCBI
27	Swingle MR, Honkanen RE and Ciszak EM: Structural basis for the catalytic activity of human serine/threonine protein phosphatase-5. J Biol Chem. 279:33992–33999. 2004. View Article : Google Scholar : PubMed/NCBI
28	Zuo Z, Dean NM and Honkanen RE: Serine/threonine protein phosphatase type 5 acts upstream of p53 to regulate the induction of p21(WAF1/Cip1) and mediate growth arrest. J Biol Chem. 273:12250–12258. 1998. View Article : Google Scholar : PubMed/NCBI
29	Zhao S and Sancar A: Human blue-light photoreceptor hCRY2 specifically interacts with protein serine/threonine phosphatase 5 and modulates its activity. Photochem Photobiol. 66:727–731. 1997. View Article : Google Scholar : PubMed/NCBI
30	Yamaguchi Y, Katoh H, Mori K and Negishi M: Galpha(12) and Galpha(13) interact with Ser/Thr protein phosphatase type 5 and stimulate its phosphatase activity. Curr Biol. 12:1353–1358. 2002. View Article : Google Scholar : PubMed/NCBI
31	Chatterjee A, Wang L, Armstrong DL and Rossie S: Activated Rac1 GTPase translocates protein phosphatase 5 to the cell membrane and stimulates phosphatase activity in vitro. J Biol Chem. 285:3872–3882. 2010. View Article : Google Scholar : PubMed/NCBI
32	Hattori K, Naguro I, Runchel C and Ichijo H: The roles of ASK family proteins in stress responses and diseases. Cell Commun Signal. 7:92009. View Article : Google Scholar : PubMed/NCBI
33	Zheng X, Zhang L, Jin B, Zhang F, Zhang D and Cui L: Knockdown of protein phosphatase 5 inhibits ovarian cancer growth in vitro. Oncol Lett. 11:168–172. 2016. View Article : Google Scholar : PubMed/NCBI
34	Zhi X, Zhang H, He C, Wei Y, Bian L and Li G: Serine/threonine protein phosphatase-5 accelerates cell growth and migration in human glioma. Cell Mol Neurobiol. 35:669–677. 2015. View Article : Google Scholar : PubMed/NCBI
35	Feng L, Sun P, Li Z, Liu M and Sun S: Knockdown of PPP5C inhibits growth of hepatocellular carcinoma cells in vitro. Appl Biochem Biotechnol. 175:526–534. 2015. View Article : Google Scholar : PubMed/NCBI
36	Liu F, Iqbal K, Grundke-Iqbal I, Rossie S and Gong CX: Dephosphorylation of tau by protein phosphatase 5: Impairment in Alzheimer's disease. J Biol Chem. 280:1790–1796. 2005. View Article : Google Scholar : PubMed/NCBI
37	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-(delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
38	Gottesman MM: Mechanisms of cancer drug resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
39	Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
40	Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:6110–6117. 1991.PubMed/NCBI
41	Li L and Leung PS: Use of herbal medicines and natural products: An alternative approach to overcoming the apoptotic resistance of pancreatic cancer. Int J Biochem Cell Biol. 53:224–236. 2014. View Article : Google Scholar : PubMed/NCBI
42	Golden T, Aragon IV, Zhou G, Cooper SR, Dean NM and Honkanen RE: Constitutive over expression of serine/threonine protein phosphatase 5 (PP5) augments estrogen-dependent tumor growth in mice. Cancer Lett. 215:95–100. 2004. View Article : Google Scholar : PubMed/NCBI
43	Amable L, Grankvist N, Largen JW, Ortsäter H, Sjöholm Å and Honkanen RE: Disruption of serine/threonine protein phosphatase 5 (PP5:PPP5c) in mice reveals a novel role for PP5 in the regulation of ultraviolet light-induced phosphorylation of serine/threonine protein kinase Chk1 (CHEK1). J Biol Chem. 286:40413–40422. 2011. View Article : Google Scholar : PubMed/NCBI
44	Jeong JY, Johns J, Sinclair C, Park JM and Rossie S: Characterization of Saccharomyces cerevisiae protein Ser/Thr phosphatase T1 and comparison to its mammalian homolog PP5. BMC Cell Biol. 4:32003. View Article : Google Scholar : PubMed/NCBI
45	Golden T, Aragon IV, Rutland B, Tucker JA, Shevde LA, Samant RS, Zhou G, Amable L, Skarra D and Honkanen RE: Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochim Biophys Acta. 1782:259–270. 2008. View Article : Google Scholar : PubMed/NCBI
46	Shirato H, Shima H, Nakagama H, Fukuda H, Watanabe Y, Ogawa K, Matsuda Y and Kikuchi K: Expression in hepatomas and chromosomal localization of rat protein phosphatase 5 gene. Int J Oncol. 17:909–912. 2000.PubMed/NCBI
47	Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, et al: Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood. 105:3722–3730. 2005. View Article : Google Scholar : PubMed/NCBI
48	Zhou G, Golden T, Aragon IV and Honkanen RE: Ser/Thr protein phosphatase 5 inactivates hypoxia-induced activation of an apoptosis signal-regulating kinase 1/MKK-4/JNK signaling cascade. J Biol Chem. 279:46595–46605. 2004. View Article : Google Scholar : PubMed/NCBI
49	Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H and Houghton PJ: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell. 11:1491–1501. 2003. View Article : Google Scholar : PubMed/NCBI
50	Michels J, Obrist F, Castedo M, Vitale I and Kroemer G: PARP and other prospective targets for poisoning cancer cell metabolism. Biochem Pharmacol. 92:164–171. 2014. View Article : Google Scholar : PubMed/NCBI
51	Hong MY, Gao JL, Cui JZ, Wang KJ, Tian YX, Li R, Wang HT and Wang H: Effect of c-Jun NH₂-terminal kinase-mediated p53 expression on neuron autophagy following traumatic brain injury in rats. Chin Med J (Engl). 125:2019–2024. 2012.PubMed/NCBI
52	Bu HQ, Liu DL, Wei WT, Chen L, Huang H, Li Y and Cui JH: Oridonin induces apoptosis in SW1990 pancreatic cancer cells via p53- and caspase-dependent induction of p38 MAPK. Oncol Rep. 31:975–982. 2014. View Article : Google Scholar : PubMed/NCBI
53	Harris SL and Levine AJ: The p53 pathway: Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005. View Article : Google Scholar : PubMed/NCBI